Blood eosinophils and serum IgE as predictors for prognosis of interferongamma therapy in atopic dermatitis

Allergy ◽  
1998 ◽  
Vol 53 (12) ◽  
pp. 1202-1207 ◽  
Author(s):  
G.W. Noh ◽  
K.Y. Lee
Keyword(s):  
Atopic Dermatitis ◽  
Serum Ige ◽  
Blood Eosinophils

scholarly journals Topical Application of Herbal Mixture Extract Inhibits Ovalbumin- or 2,4-Dinitrochlorobenzene-Induced Atopic Dermatitis

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Soon Re Kim ◽  
Han-Seok Choi ◽  
Hye Sook Seo ◽  
Youn Kyung Choi ◽  
Yong Cheol Shin ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Topical Application ◽  
Immunoglobulin E ◽  
Elevated Serum ◽  
Ethanol Extract ◽  
Inflammatory Cells ◽  
Skin Lesions ◽  
Serum Ige ◽  
Beneficial Effects ◽  
Blood Eosinophils

KM110329 is four traditional herbal medicine mixtures with anti-inflammatory properties. Atopic dermatitis (AD) is an inflammatory skin disease associated with enhanced T-helper2 (Th2) lymphocyte response to allergens that results in elevated serum eosinophil and Immunoglobulin E (IgE) levels and leukocyte infiltration in atopic skin sites. In this study, we investigated the effect of topical application of KM110329 ethanol extract on the ovalbumin (OVA) or 2,4-dinitrochlorobenzene- (DNCB-) induced AD mouse models. For that purpose, we observed the effects of KM110329 on blood eosinophils, skin mast cells, production of serum IgE, and expression of cytokine mRNA in the atopic dermatitis skin lesions of OVA allergen- or DNCB-treated BALB/c mice. KM110329 significantly reduced blood eosinophils cell numbers in OVA or DNCB-treated BALB/c mice. Histological analyses demonstrated decreased mast cell count as well as dermal infiltration by inflammatory cells. In the skin lesions, mRNA expression of interleukine (IL)-4, IL-13, and IL-17 was inhibited by KM110329. KM110329 also suppressed the production of serum IgE level in both the OVA- and DNCB-induced atopic dermatitis model. Taken together, our results showed that topical application of KM110329 extracts exerts beneficial effects in AD symptoms, suggesting that KM110329 might be a useful candidate for the treatment of AD.

scholarly journals Transcriptomic analysis of atopic dermatitis in African Americans is characterized by Th2/Th17-centered cutaneous immune activation

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Shannon Wongvibulsin ◽  
Nishadh Sutaria ◽  
Suraj Kannan ◽  
Martin Prince Alphonse ◽  
Micah Belzberg ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
African Americans ◽  
Immune Activation ◽  
Population Level ◽  
Research Network ◽  
Variation Analysis ◽  
Immune Signature ◽  
Key Drivers ◽  
Blood Eosinophils ◽  
Level Analysis

AbstractAtopic dermatitis (AD) often presents more severely in African Americans (AAs) and with greater involvement of extensor areas. To investigate immune signatures of AD in AAs with moderate to severe pruritus, lesional and non-lesional punch biopsies were taken from AA patients along with age-, race-, and sex-matched controls. Histology of lesional skin showed psoriasiform dermatitis and spongiotic dermatitis, suggesting both Th2 and Th17 activity. Gene Set Variation Analysis showed upregulation of Th2 and Th17 pathways in both lesional versus non-lesional and lesional versus control (p < 0.01), while Th1 and Th22 upregulation were observed in lesional versus control (p < 0.05). Evidence for a broad immune signature also was supported by upregulated Th1 and Th22 pathways, and clinically may represent greater severity of AD in AA. Furthermore, population-level analysis of data from TriNetX, a global federated health research network, revealed that AA AD patients had higher values for CRP, ferritin, and blood eosinophils compared to age-, sex-, and race-matched controls as well as white AD patients, suggesting broad systemic inflammation. Therefore, AA AD patients may feature broader immune activation than previously thought and may derive benefit from systemic immunomodulating therapies that modulate key drivers of multiple immune pathways.

Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients

1998 ◽  
Vol 12 (14) ◽  
pp. 1559-1569 ◽  
Author(s):  
Susanne Natter ◽  
Susanne Seiberler ◽  
Peter Hufnagl ◽  
Bernd R. Binder ◽  
Alexander M. Hirschl ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Cdna Clones ◽  
Serum Ige

scholarly journals Indigo Pulverata Levis (Chung-Dae, Persicaria tinctoria) Alleviates Atopic Dermatitis-like Inflammatory Responses In Vivo and In Vitro

2022 ◽  
Vol 23 (1) ◽  
pp. 553
Author(s):  
Ga-Yul Min ◽  
Ji-Hye Kim ◽  
Tae-In Kim ◽  
Won-Kyung Cho ◽  
Ju-Hye Yang ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Immune Cell ◽  
Cell Infiltration ◽  
Immune Cell Infiltration ◽  
Hacat Cells ◽  
Serum Ige ◽  
Tnf Α ◽  
Inflammatory Chemokines

Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with a type 2 T helper cell (Th2) immune response. The IndigoPulverata Levis extract (CHD) is used in traditional Southeast Asian medicine; however, its beneficial effects on AD remain uninvestigated. Therefore, we investigated the therapeutic effects of CHD in 2,4-dinitrochlorobenzene (DNCB)-induced BALB/c mice and tumor necrosis factor (TNF)-α- and interferon gamma (IFN)-γ-stimulated HaCaT cells. We evaluated immune cell infiltration, skin thickness, and the serum IgE and TNF-α levels in DNCB-induced AD mice. Moreover, we measured the expression levels of pro-inflammatory cytokines, mitogen-activated protein kinase (MAPK), and the nuclear factor-kappa B (NF-κB) in the mice dorsal skin. We also studied the effect of CHD on the translocation of NF-κB p65 and inflammatory chemokines in HaCaT cells. Our in vivo results revealed that CHD reduced the dermis and epidermis thicknesses and inhibited immune cell infiltration. Furthermore, it suppressed the proinflammatory cytokine expression and MAPK and NF-κB phosphorylations in the skin tissue and decreased serum IgE and TNF-α levels. In vitro results indicated that CHD downregulated inflammatory chemokines and blocked NF-κB p65 translocation. Thus, we deduced that CHD is a potential drug candidate for AD treatment.

Serum IgE for Bet v 1 in Patients Affected by Atopic Dermatitis

2011 ◽  
Vol 9 (2) ◽  
pp. 205-207 ◽  
Author(s):  
G. Ciprandi ◽  
M. De Amici ◽  
L. Berardi ◽  
M. Vignini ◽  
G. Marseglia
Keyword(s):  
Atopic Dermatitis ◽  
Serum Ige ◽  
Bet V 1

scholarly journals Metabolomics Distinguishes DOCK8 Deficiency from Atopic Dermatitis: Towards a Biomarker Discovery

Metabolites ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. 274 ◽  
Author(s):  
Minnie Jacob ◽  
Xinyun Gu ◽  
Xian Luo ◽  
Hamoud Al-Mousa ◽  
Rand Arnaout ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Biomarker Discovery ◽  
Isotope Labeling ◽  
Immunoglobulin E ◽  
Clinical Symptoms ◽  
Elevated Serum ◽  
Severe Atopic Dermatitis ◽  
Serum Ige ◽  
Tryptophan Degradation ◽  
Dock8 Deficiency

Bi-allelic mutations in the dedicator of cytokinesis 8 (DOCK8) are responsible for a rare autosomal recessive primary combined immunodeficiency syndrome, characterized by atopic dermatitis, elevated serum Immunoglobulin E (IgE) levels, recurrent severe cutaneous viral infections, autoimmunity, and predisposition to malignancy. The molecular link between DOCK8 deficiency and atopic skin inflammation remains unknown. Severe atopic dermatitis (AD) and DOCK8 deficiency share some clinical symptoms, including eczema, eosinophilia, and increased serum IgE levels. Increased serum IgE levels are characteristic of, but not specific to allergic diseases. Herein, we aimed to study the metabolomic profiles of DOCK8-deficient and AD patients for potential disease-specific biomarkers using chemical isotope labeling liquid chromatography-mass spectrometry (CIL LC-MS). Serum samples were collected from DOCK8-deficient (n = 10) and AD (n = 9) patients. Metabolomics profiling using CIL LC-MS was performed on patient samples and compared to unrelated healthy controls (n = 33). Seven metabolites were positively identified, distinguishing DOCK8-deficient from AD patients. Aspartic acid and 3-hydroxyanthranillic acid (3HAA, a tryptophan degradation pathway intermediate) were up-regulated in DOCK8 deficiency, whereas hypotaurine, leucyl-phenylalanine, glycyl-phenylalanine, and guanosine were down-regulated. Hypotaurine, 3-hydroxyanthranillic acid, and glycyl-phenylalanine were identified as potential biomarkers specific to DOCK8 deficiency. Aspartate availability has been recently implicated as a limiting metabolite for tumour growth and 3HAA; furthermore, other tryptophan metabolism pathway-related molecules have been considered as potential novel targets for cancer therapy. Taken together, perturbations in tryptophan degradation and increased availability of aspartate suggest a link of DOCK8 deficiency to oncogenesis. Additionally, perturbations in taurine and dipeptides metabolism suggest altered antixidation and cell signaling states in DOCK8 deficiency. Further studies examining the mechanisms underlying these observations are necessary.

Effect of Acupuncture on Allergic Rhinitis: Clinical and Laboratory Evaluations

1975 ◽  
Vol 03 (03) ◽  
pp. 263-270 ◽  
Author(s):  
Benjamin H. S. Lau ◽  
Douglas S. Wong ◽  
James M. Slater
Keyword(s):  
Allergic Rhinitis ◽  
Clinical Assessment ◽  
Laboratory Tests ◽  
Point Scale ◽  
Serum Ige ◽  
Moderate Reduction ◽  
Clinical Rating ◽  
Blood Eosinophils

Of 22 subjects with allertic rhinitis who received a series of 6 acupuncture treatments, 11 (50%) were virtually symptom-free by the end of the series, 8 (36%) experienced a moderate reduction in symptoms, and 3 (14%) recieved no significant relief. Clinical assessment of symptoms was made on a 6-point scale before the first treatment and before each subsequent session. Laboratory tests included absolute blood eosinophils, percentage of nasal eosinophils, and radioimmunoassy of serum IgE, performed before the first treatment, at the end of the series, and 2 months later. A siginificant decrease in subjective clinical rating symptoms correlated with a concurrent drop in absolute numbers of blood eosinophils and percentage of nasal eosinophils. IgE levels decreased in 64% of the subjects by completion of treatment and in 76% at 2-month follow-up.

Sign in / Sign up

Export Citation Format

Share Document